Xiaojie Zhang

Beijing Tiantan Biological Products Co., Ltd., Chaoyang, 100024, Beijing, China
Author    Correspondence author
Journal of Vaccine Research, 2024, Vol. 14, No. 5   
Received: 27 Aug., 2024    Accepted: 09 Oct., 2024    Published: 29 Oct., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The rapid development of mRNA vaccine technology during the COVID-19 pandemic has revolutionized the field of immunization. This study explores key advancements in mRNA vaccine formulations, focusing on their mechanisms of action, delivery systems, and improvements in stability and efficacy. The success of mRNA vaccines developed by Pfizer-BioNTech and Moderna highlights the potential of this platform in addressing various infectious diseases. Beyond COVID-19, mRNA vaccines are also being researched for applications in cancer immunotherapy, autoimmune diseases, and other chronic conditions. Recent innovations, such as lipid nanoparticle (LNP) optimization, thermostable formulations, and immune modulators, are crucial for expanding the use of mRNA vaccines in global health. The report also discusses regulatory and ethical considerations, including accelerated approval processes and challenges in global vaccine access. As mRNA vaccine technology continues to evolve, its role in personalized medicine and global health will grow, offering new opportunities to combat emerging infectious diseases and non-communicable diseases.

mRNA vaccines; Lipid nanoparticles; COVID-19; Cancer immunotherapy; Global health